Satoria Pharma

Satoria Pharma is a UK-based biotechnology company focused on developing novel therapeutic approaches for Type 2 Diabetes. Backed by Medicxi, the company operates under an asset-centric model, concentrating its resources on a specific metabolic program. Its lead research aims to address the underlying pathophysiology of diabetes through innovative small molecule interventions. The company's primary focus is on the development of GPR119 agonists, which are designed to enhance insulin secretion and improve glucose homeostasis. Satoria Pharma is part of a cluster of companies founded by Medicxi partners to advance high-potential assets through early-stage clinical development.